Point72 Europe’s ResMed RMD Stock Holding History

Point72 Europe’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-17,343	Closed	-$3.79M	–	122
2023 Q2	$3.79M	Buy	+17,343	New	+$3.87M	0.5%	60

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Point72 Europe's RMD Position: Q3 2023 in Review

Point72 Europe sold out of ResMed (RMD) in Q3 2023, closing a stake of 17,343 shares — an estimated $3.79M sold.

Point72 Europe first reported a position in RMD in Q2 2023 and held it in 1 quarter. The position peaked at $3.79M in Q2 2023. 657 funds tracked by Wall St. Rank hold RMD as of Q3 2023.

Point72 Europe reported no remaining ResMed position as of Q3 2023 after selling out during the quarter.
Point72 Europe sold 17,343 ResMed shares in Q3 2023, an estimated $3.79M.
Point72 Europe first reported a position in ResMed in Q2 2023 and held it in 1 quarter.
Point72 Europe's ResMed position peaked at $3.79M in Q2 2023.
657 funds tracked by Wall St. Rank held ResMed as of Q3 2023.

Based on Point72 Europe's 13F filing for Q3 2023, filed 14 Nov 2023.